Provided by Tiger Fintech (Singapore) Pte. Ltd.

Timber Pharmaceuticals

0.3426
0.0000
Volume:- -
Turnover:108.12K
Market Cap:1.06M
PE:-0.07
High:0.3426
Open:0.3426
Low:0.3426
Close:0.3426
52wk High:3.39
52wk Low:0.0585
Shares:3.09M
Float Shares:2.79M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.9748
EPS(LYR):-9.1927
ROE:-343.24%
ROA:-137.27%
PB:-0.40
PE(LYR):-0.04

Loading ...

Company Profile

Company Name:
Timber Pharmaceuticals
Exchange:
AMEX
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.